Room For More? Karyopharm Targets Highly Refractory Myeloma Patients

Crowded field of multiple myeloma has yet another contender – Karyopharm's first-in-class SIN/XPO1 antagonist selinexor – but company thinks "penta-refractory" approach will be a good calling card.